ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Efficacy of combined metformin plus progestin therapy versus progestin monotherapy in endometrial hyperplasia: a randomized clinical trial.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progesterone is the standard therapy for endometrial hyperplasia, but the added benefit of metformin on histological remission and metabolic outcomes remains unclear. This study aims to compare the efficacy and safety of progestin monotherapy versus metformin plus progestin therapy in women with endometrial hyperplasia. The trial design is a single-center, open-label, parallel-group, randomized clinical trial conducted at Kosar Hospital, Qazvin, Iran, between May 2023 and July 2024. One hundred women aged 18-55 years with histologically confirmed endometrial hyperplasia were randomized 1:1 to receive progestin alone (n = 50) or metformin plus progestin (n = 50). Progestin monotherapy was administered as megestrol acetate 40 mg daily (atypical hyperplasia) or medroxyprogesterone acetate 10 mg/day cyclically (non-atypical). The combination group received the same progestin regimen plus metformin 500 mg twice daily for 3 months. All participants completed follow-up. At 3 months, histological remission was achieved in 82% (41/50) of the progestin group and 76% (38/50) of the combination group (adjusted RR 0.94; 95% CI 0.76-1.16; p = 0.56). At 6 months, remission rates were 92% and 88%, respectively (adjusted RR 0.98; 95% CI 0.86-1.11; p = 0.76). Addition of metformin was associated with a statistically significant but very modest reduction in BMI over 6 months (adjusted mean difference - 0.15 kg/m
Indexed as
Identifiers
42624928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.